Restenosis revisited

Circ Res. 2009 Apr 10;104(7):823-5. doi: 10.1161/CIRCRESAHA.109.196345.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Cardiovascular Agents / administration & dosage
  • Cardiovascular Agents / therapeutic use*
  • Carotid Stenosis / drug therapy*
  • Carotid Stenosis / enzymology
  • Carotid Stenosis / pathology
  • Cell Proliferation / drug effects
  • Coronary Restenosis / enzymology
  • Coronary Restenosis / pathology
  • Coronary Restenosis / prevention & control*
  • Drug-Eluting Stents
  • Enzyme Activation
  • Enzyme Activators / administration & dosage
  • Enzyme Activators / therapeutic use*
  • Humans
  • Hyperplasia
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / enzymology
  • Muscle, Smooth, Vascular / pathology
  • NAD(P)H Dehydrogenase (Quinone) / antagonists & inhibitors
  • NAD(P)H Dehydrogenase (Quinone) / genetics
  • NAD(P)H Dehydrogenase (Quinone) / metabolism*
  • Naphthoquinones / administration & dosage
  • Naphthoquinones / therapeutic use*
  • Secondary Prevention
  • Tunica Intima / drug effects
  • Tunica Intima / enzymology
  • Tunica Intima / pathology

Substances

  • Cardiovascular Agents
  • Enzyme Activators
  • Naphthoquinones
  • beta-lapachone
  • NAD(P)H Dehydrogenase (Quinone)
  • NQO1 protein, human
  • NQO1 protein, rat